Virica Biotech

Every day that viral vector production is delayed, patients wait longer for life-changing treatments and biotech companies face increased costs and lost revenue. But what's slowing things down? 🔹 Low vector yields, which require multiple production runs 🔹 Inefficient process development causing bottlenecks The solution? CDMOs and biotech companies are leveraging upstream yield optimization, process automation, and innovative yield-enhancing technologies to accelerate viral vector manufacturing, cutting production timelines and making therapies more accessible. 💡 By combining eXmoor Pharma’s deep knowledge in AAV biomanufacturing and high-performance platform with Virica’s innovative VSE technology, we are addressing key bottlenecks in AAV production and helping to accelerate the development of next-generation cell and gene therapies. ✔️ Read Full Article: https://lnkd.in/eCjf55tV #genetherapy #biomanufacturing #viralvector #biotechinnovation

📣 It’s Friday and we are back with another “Ask a Virologist” segment! AAV is the workhorse viral vector for most gene therapies. With ~6 approved AAV-based gene therapies and many on the horizon, Keara Sutherland, dives into a quick history of AAV and its rise to prominence! 👇 Check out the video below for a quick history of AAV! Which viral vector do you want to see next? Drop it in the comments below! If you liked the videos in these series follow us! #AAV #genetherapy #askavirologist 

📣 We are thrilled to announce that Virica Biotech will present at Advanced Therapies London! Drop by our poster presentation to check out our collaboration data with REITHERA! 📍 Where to find us: Poster Zone #14 🗓️ When: 10:50 am GMT, March 19 Don’t miss this opportunity to learn how combining these technologies can drive your gene therapy projects forward! 💡 Looking to drive up CGT manufacturing productivity and drive down COGS?   Check out our collaboration data: https://lnkd.in/d7k3wxGH #biomanufacturing #innovation #AdvancedTherapies

High viral vector manufacturing costs are a major obstacle in gene therapy, but manufacturing viral vectors at scale doesn't have to mean higher costs. 💡 Cell enhancers such as Viral Sensitizers (VSE™) offer a powerful and flexible solution to rapidly optimize upstream viral vector yields without major CAPEX investments. Using VSE technology, you can: ✔ Enhance viral vector production efficiency without altering existing workflows. ✔ Reduce variability across batches, improving reproducibility at scale. ✔ Lower cost-per-dose by increasing vector yield. Curious about the data? See our solution in action: https://lnkd.in/dnEdkcRc #genetherapy #biomanufacturing #bioprocessing #viralvector #innovation

We look forward to collaborating with Culture Biosciences for an upcoming webinar on leveraging cloud-connected bioreactors to enhance in-house capabilities for AAV and lentivirus development. Our speakers will showcase a next-generation bioreactor system that enables seamless workflows, external scalability, and accelerated, high-quality results. 📅 Secure your spot today! Register now: https://bit.ly/41IfXAV

After an engaging day in Molsheim, France, our Head of Viral Vector, Daphné Bocciarelli, shares her reflections on the "Learn & Connect 2025 - Viral Gene Therapy" event, which focused on gene therapy manufacturing and quality control. 💡 What stood out? The event was packed with insightful talks and meaningful discussions, and it was a fantastic opportunity to connect with industry experts. There was significant interest in our partnership with Virica Biotech, particularly in how our ongoing scale-up work is advancing AAV manufacturing efficiency. Daphné’s key takeaways: 🔹 Regulatory challenges remain a barrier to adopting faster, more precise QC analytics for release testing and dosing assays. 🔹 Next-Generation Sequencing (NGS) is proving to be a powerful tool for assessing product quality at every stage of development. 🔹 Platform processes continue to divide opinion—while challenging, they are becoming an essential starting point for process development to meet clinical and investment milestones. 🔹 Could affinity columns be the next breakthrough for host cell protein (HCP) removal? 🔹 Automation is already transforming environmental monitoring, freeing up skilled scientists for higher-value tasks. A huge thank you to Merck Life Science for hosting this insightful event and to Virica Biotech for allowing us to showcase our collaborative project. Events like these are invaluable in advancing innovation in viral vector manufacturing. #GeneTherapy #AAV #ViralVectors #Bioprocessing #Automation #NGS #ProcessDevelopment #CellAndGeneTherapy #eXmoorPharma

📽️ It's Friday, and that means we are back in another “Ask a Virologist” Segment! 💡 Liquid handlers play a big role in Virica’s automation and high throughput virology, significantly boosting lab productivity. But choosing the liquid handler for the job can be tricky. How do you know what liquid handler is right for the task? 👇 Our expert Glib Maznyi, breaks down the important aspects to consider when choosing a liquid handler for your automation needs. Got burning questions on liquid handlers or like to geek out with the benchtop tech? Shoot us a DM or drop it in the comments below! We’d love to know! Follow us to stay tuned for upcoming videos! #biomanufacturing #innovation #askavirologist

📣 Advanced Therapies London is around the corner and we'd love to see you there! Meet with Azra Benson and Zeeshan Shaikh, to learn about how leveraging our Viral Sensitizers (VSEᵀᴹ) and Design of Experiments (DoE) -powered workflows unlock:   ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing COGS. 📣 Looking to drive up CGT manufacturing productivity and drive down COGS?   A brief overview of our technology: https://lnkd.in/gu2m3RcX #biomanufacturing #innovation #AdvancedTherapies #cellandgenetherapy

It's no secret that cell and gene therapy manufacturing is incredibly expensive. Some of the factors driving up costs include: - Limited vector yields per batch, increasing per-dose pricing - Need for higher titers to meet demand for commercial-scale production - Process inefficiencies leading to high COGS (Cost of Goods Sold) 💬 CGT manufacturing is complex and there is no "silver bullet" to improve efficiency and bring down COGs. A winning strategy involves a layered approach. Innovations such as stable producer cell lines, cell enhancer technologies and automation are essential to improve productivity and reduce costs. #biomanufacturing #innovation #cellandgenetherapy #viralvector #genetherapy #aavmanufacturing

📣 eXmoor Pharma’s Head of Viral Vector, Daphné Bocciarelli, will present exciting collaboration data at 'Learn & Connect 2025 – Viral Gene Therapy' today in Molsheim, France. 💡 Daphné will share insights from our collaboration with eXmoor Pharma, focusing on optimizing AAV process performance by integrating Virica’s VSE™ technology with eXmoor’s AAV platform. The initiative aims to enhance AAV yields through scalable upstream improvements, accelerate development with a flexible, serotype-agnostic platform, and reduce costs using VSEs for manufacturing efficiency. Check out how VSEs can transform your AAV manufacturing: https://lnkd.in/dnEdkcRc #innovation #biomanufacturing #AAV